.RESEARCH STUDY FEATURE.06 August 2024.
A big randomized measured trial along with cisgender females highlights the obstacles of adherence to a regular oral preexposure prevention regiment as well as shows that twice-yearly treatment of lenacapavir can easily keep efficient HIV deterrence degrees over 6 months.